Last reviewed · How we verify

NCT07126717

Acute Effects of Zynamite® S in Cognitive Function and Mood

Completed NA Last updated 17 August 2025
What this trial tests

NA trial testing Placebo in Cognitive Performance in 88 participants. Completed in 9 June 2025.

Timeline
12 May 2025
Primary endpoint
2 June 2025
9 June 2025

Quick facts

Lead sponsorNektium Pharma SL
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment88
Start date12 May 2025
Primary completion2 June 2025
Estimated completion9 June 2025
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Nektium Pharma SL

Who can join

Adults 18 to 25, any sex, with Cognitive Performance or Mood. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study sought to confirm the cognitive and mood benefits of a standardized soluble mango leaf extract, named as Zynamite® S. A placebo or a single dose of the botanical extract (100 mg) was administered and its acute effects on mental function and mood were evaluated before product intake, at 30 min, 3 h, and 5 h post-ingestion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cognitive Performance

Currently open trials in the same condition.

Other Nektium Pharma SL trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07126717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing